Sequenom Launches MaterniT21 Down Syndrome Test as LDT, Publishes Clinical Validation Study | GenomeWeb

By Monica Heger

This story was originally published Oct. 17.

Sequenom said this week that it has launched its noninvasive lab-developed sequencing-based test for Down syndrome in 20 US metropolitan areas and has published a clinical validation study for the test in the journal Genetics in Medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.